ACTON, Mass., Feb. 23, 2012 /PRNewswire/ -- Psychemedics Corporation (NASDAQ: PMD) today announced fourth quarter and year-end financial results for the period ended December 31, 2011. The Company also announced an increase in the quarterly dividend to $0.15 per share payable to shareholders of record as of March 5, 2012 to be paid on March 19, 2012. This will be the Company’s 62nd consecutive quarterly dividend.
The Company's revenue for the year ended December 31, 2011 was $24.1 million, an increase of 20% as compared to $20.1 million for 2010. Net income for the year ended December 31, 2011 was $3.5 million or $0.67 per share, an increase of 34% from 2010 during which the Company earned $2.6 million or $0.50 per share. Revenue for the fourth quarter was $5.5 million, an increase of 8% as compared to $5.1 million in the fourth quarter of 2010. Net income for the quarter was $438 thousand or $0.08 per share, an increase of 5% from $417 thousand or $0.08 per share for the same period of 2010.
Raymond C. Kubacki, Chairman and Chief Executive Officer, said, "In 2011, sales and profits continued on the growth track. While we are very proud that we have been profitable every year since 1993, including the severe 2009 recession, our focus continues to be sales and earnings growth. The growth in 2011 can be attributed almost exclusively to the addition of new customers and introducing new programs to existing customers."
Kubacki continued: "Beyond the strong financial performance of 2011, the Company has made several investments in the future. In December, the Company received its 7th patent, which focuses on liquefying hair and releasing drugs trapped in the hair without destroying the drugs. The new patented method can be used with a broad range of immunoassay screen techniques, mass spectrometry methods, and chromatographic procedures. This patent is fundamental to hair analysis drug testing because if you cannot get the drugs out of the hair, the drugs cannot be measured. In addition, the Company received international accreditation (ISO/IEC 17025:2005) for a broad spectrum of laboratory testing including drugs of abuse and forensics in hair and urine specimens in the fourth quarter. The International Organization for Standardization/International Electrotechnical Commission (ISO/IEC) 17025 accreditation confirms international compliance and technical competence of the laboratory. This additional recognition affirms to our growing number of international clients, as well as domestic clients, that they are partnered with one of the highest quality laboratories anywhere in the world. Finally, the Company has continued to invest in Sales and Marketing with additional staff and innovative programs."
Kubacki continued: "This year also marks the Company's 25 year anniversary milestone. Since pioneering the use of hair testing for drugs of abuse over 25 years ago, Psychemedics has achieved global recognition as an innovative organization and technology leader in the field of drug testing. While the Company is proud to celebrate our history and significant achievements over the past 25 years, we look to the future for even greater success."
Kubacki concluded, "The Company's balance sheet remains strong with approximately $5.6 million in cash and cash equivalents and no long-term debt. Our directors share our confidence in the future of Psychemedics and remain committed to rewarding shareholders and sharing the financial success of the Company with them as we grow. Therefore, we are pleased to declare a 25% increase in our quarterly dividend to $0.15 per share. This dividend represents our sixty-second consecutive quarterly dividend.”
Psychemedics is the world's largest provider of hair testing for drugs of abuse with thousands of corporations relying on the patented Psychemedics drug testing services. Psychemedics' clients include over 10% of the Fortune 500, some of the largest police departments in America and six Federal Reserve Banks.
The Psychemedics web site is http://www.psychemedics.com/
Cautionary Statement for purposes of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995: From time to time, information provided by Psychemedics may contain forward-looking information that involves risks and uncertainties. In particular, statements contained in this release that are not historical facts (including but not limited to statements concerning earnings, earnings per share, revenues, dividends, future business, new accounts, customer base, market share, test volume sales, marketing strategies, and technological advantages) may be "forward looking" statements. Actual results may differ from those stated in any forward-looking statements. Factors that may cause such differences include but are not limited to risks associated with the expansion of the Company's sales and marketing network, technological developments, intellectual property protection, development of markets for new products and services offered, the economic health of principal customers of the Company, government regulation, including but not limited to FDA regulations, competition and general economic conditions and other factors disclosed in the Company's filings with the Securities and Exchange Commission.
Neil Lerner Vice President Finance (978) 206-8220 Neill@psychemedics.com
Statements of Income
Three Months Ended
Twelve Months Ended
Cost of revenues
General & administrative
Marketing & selling
Research & development
Total operating expenses
Net income before provision for income taxes
Provision for income taxes
Basic net income per share
Diluted net income per share
Dividends declared per share
Weighted average common shares outstanding, basic
Weighted average common shares outstanding, diluted
Cash and cash equivalents
Accounts receivable, net of allowance for doubtful accounts
of $169,191 in 2011 and $119,295 in 2010
Prepaid expenses and other current assets
Income tax receivable
Deferred tax assets
Total Current Assets
Equipment & leasehold improvements
Less accumulated depreciation
Net Fixed Assets
LIABILITIES AND SHAREHOLDERS' EQUITY
Total Current Liabilities
Deferred tax liabilities, long term
Preferred-stock, $0.005 par value, 872,521 shares authorized,
no shares issued or outstanding
Common stock, $0.005 par value; 50,000,000 shares authorized
5,903,552 shares issued in 2011 and 5,877,358 shares issued in 2010
Less - Treasury stock, at cost, 668,130 shares in 2011 and 665,345 shares in 2010
Total Shareholders' Equity
Total Liabilities and Shareholders' Equity
SOURCE Psychemedics Corporation